EXOZ vs GEVO

Analysts rate Gevo, Inc.

(GEVO) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, eXoZymes, Inc.

(EXOZ) delivered a total return of +15. 6%, compared to -65. 2% for Gevo, Inc. (GEVO). Over 10 years, the gap is even starker: EXOZ returned +15. 6% versus GEVO's -98. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), eXoZymes, Inc.

(EXOZ) is the lower-risk stock at 1. 04β versus Gevo, Inc. 's 1. 64β — meaning GEVO is approximately 59% more volatile than EXOZ relative to the S&P 500. On balance sheet safety, eXoZymes, Inc. (EXOZ) carries a lower debt/equity ratio of 13% versus 36% for Gevo, Inc. — giving it more financial flexibility in a downturn.

On earnings-per-share growth, the picture is similar: Gevo, Inc.

grew EPS 58. 8% year-over-year, compared to -188. 0% for eXoZymes, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

eXoZymes, Inc.

(EXOZ) is the more profitable company, earning 0. 0% net margin versus -21. 1% for Gevo, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: EXOZ leads at 0. 0% versus -11. 7% for GEVO. At the gross margin level — before operating expenses — GEVO leads at 30. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, eXoZymes, Inc.

(EXOZ) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 04)). Gevo, Inc. (GEVO) carries a higher beta of 1. 64 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (EXOZ: +15. 6%, GEVO: -98. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (EXOZ (Healthcare) and GEVO (Basic Materials)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: EXOZ is a small-cap quality compounder stock; GEVO is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.